These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23680477)

  • 1. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Lin TS
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
    Friedberg JW
    Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
    Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic lymphocytic leukemia].
    Aoki S
    Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
    Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
    Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
    [No Abstract]   [Full Text] [Related]  

  • 10. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging immunological drugs for chronic lymphocytic leukemia.
    Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treanda approved for chronic lymphocytic leukemia.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
    [No Abstract]   [Full Text] [Related]  

  • 13. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
    Chen CI
    Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-of-the-art treatment of chronic lymphocytic leukemia.
    Hallek M
    Hematology Am Soc Hematol Educ Program; 2009; ():440-9. PubMed ID: 20008230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Cramer P; Eichhorst B; Reinhardt HC; Hallek M
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy-free treatment of chronic lymphocytic leukemia?].
    Wendtner CM
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2104-6. PubMed ID: 24085367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
    Hill BT; Caimi P; Kindwall-Keller T; Habecker B; Kalaycio M
    Br J Haematol; 2014 Jan; 164(2):297-9. PubMed ID: 24131326
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.